MG
TRIL

Michael Gelband’s Trillium Therapeutics Inc. TRIL Stock Holding History

Michael Gelband’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-56,296
Closed -$828K – 2798
2020
Q4 		$828K Buy
56,296
+25,486
+83% +$368K 0.01% 966
2020
Q3 		$438K Sell
30,810
-94,990
-76% -$947K 0.01% 1087
2020
Q2 		$1.02M Buy
125,800
+90,800
+259% +$562K 0.03% 737
2020
Q1 		$141K Buy
+35,000
New +$132K 0.01% 846

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Michael Gelband's TRIL Position: Q1 2021 in Review

Michael Gelband sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 56,296 shares — an estimated $828K sold.

Michael Gelband first reported a position in TRIL in Q1 2020 and held it in 4 quarters. The position peaked at $1.02M in Q2 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • Michael Gelband reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • Michael Gelband sold 56,296 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $828K.
  • Michael Gelband first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 4 quarters.
  • Michael Gelband's Trillium Therapeutics Inc. position peaked at $1.02M in Q2 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on ExodusPoint Capital Management's 13F filing for Q1 2021, filed 17 May 2021.